Rheumatoid Arthritis
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.
The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations. Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.
Dr. John Cush RheumNow
2 years ago
How do we manage difficult discussions about pregnancy in RA?
Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though...
https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8
ARD & RMD Open ARD_BMJ
2 years ago
L20 at #ACR23
Phase 3 RCT of #Telitacicept vs. placebo in #RA
☝🏻B-cell neutralization by targeting BlyS and APRIL
✅ better ACR20 and 50 response at W24
✅ favorable structural response
✅ good safety profile
❓ few seronegative patients
A new small molecule to treat #RA?
PAJ https://t.co/fyrqAya41e
Elena MyasoedovaMD ☀️
2 years ago
#ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia:
👉🏻CVD is not a signif mediator b/w RA &Dementia
👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD)
👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD
#Mayoclinicrheumatology https://t.co/5kqs3HAACn
Jeffrey Sparks MD MMSc jeffsparks
2 years ago
Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation!
#ACR23 https://t.co/P7keAoOX7M
Tue Kragstrup KragstrupTW
2 years ago
Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia).
Prof Taylor presents that it might work in CCP high titer RA at #ACR23.
#ACRambassador @ACRheum https://t.co/DqlsOv7AVI
Janet Pope
2 years ago
B cell signalling reduction to treat #RA?
Telitacicept RCT showed #efficacy in active RA w MTX -maybe blunted high responses but no active comparator, only #PBO so difficult to compare to current Rx and only from 1 country China. Past bDMARDs not reported
L20 @RheumNow @ACRheum
David Liew drdavidliew
2 years ago
As per #ACR23 ABST0433, what % of RA patients on US Medicare are on a DMARD within 1y of diagnosis?
I'm not talking your choice of b/tsDMARD.
I'm talking any cs/b/tsDMARD of any sort.
Hear from @JihaRheum to skip to the answer:
https://t.co/lI2M20JWKC
Truly stunning. @RheumNow
Dr. John Cush RheumNow
2 years ago
Sex bias in RA: time to stop blaming hormones?
https://t.co/uPq87r4Ndv https://t.co/Yleu2LDV3g
Richard Conway
2 years ago
Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07
Poster Hall